Timothy R Morgan

Summary

Country: USA

Publications

  1. ncbi Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
  2. ncbi Chemoprevention of hepatocellular carcinoma in chronic hepatitis C
    Timothy R Morgan
    Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA 90822, USA
    Recent Results Cancer Res 188:85-99. 2011
  3. ncbi DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    J Hepatol 49:548-56. 2008
  4. ncbi Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 140:840-9; quiz e12. 2011
  5. ncbi Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
  6. ncbi Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 136:138-48. 2009
  7. ncbi Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Hepatology 49:1828-37. 2009
  8. ncbi Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 138:493-502. 2010
  9. ncbi Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Am J Gastroenterol 106:884-93. 2011
  10. ncbi Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 138:2321-31, 2331.e1-2. 2010

Detail Information

Publications22

  1. ncbi Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    Hepatology 52:833-44. 2010
    ..CONCLUSION: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC...
  2. ncbi Chemoprevention of hepatocellular carcinoma in chronic hepatitis C
    Timothy R Morgan
    Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA 90822, USA
    Recent Results Cancer Res 188:85-99. 2011
    ..Overall, these data suggest that chemoprevention of hepatocellular carcinoma in patients with chronic hepatitis C is an achievable objective...
  3. ncbi DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial
    Timothy R Morgan
    Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
    J Hepatol 49:548-56. 2008
    ..As part of the HALT-C trial we evaluated genetic associations among patients infected with HCV genotype 1 who had failed previous interferon treatment...
  4. ncbi Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 140:840-9; quiz e12. 2011
    ..We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period...
  5. ncbi Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  6. ncbi Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 136:138-48. 2009
    ..We evaluated the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort for the incidence of HCC and associated risk factors...
  7. ncbi Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Hepatology 49:1828-37. 2009
    ..Decreased alcohol intake and improved metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C progression...
  8. ncbi Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma
    Anna S Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Gastroenterology 138:493-502. 2010
    ..The aim of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in the early diagnosis of HCC...
  9. ncbi Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Am J Gastroenterol 106:884-93. 2011
    ..The objective of this study was to determine the incidence and risk factors associated with new-onset and worsening portal hypertensive gastropathy (PHG) in patients with chronic hepatitis C (CHC)...
  10. ncbi Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C
    Robert J Fontana
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 138:2321-31, 2331.e1-2. 2010
    ..We aimed to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis...
  11. ncbi Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver
    Elango Kathirvel
    Research Service, VA Long Beach Healthcare System, Long Beach, California 90822, USA
    J Gastroenterol Hepatol 25:1136-43. 2010
    ..In the present study, we evaluate gene expression, protein content and activity of anti-oxidant enzymes, and iNOS, in a CYP2E1 overexpressing model of non-alcoholic fatty liver (NAFL)...
  12. ncbi Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C
    Anna S Lok
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Hepatology 54:434-42. 2011
    ..In the United States, neither previous nor occult HBV infection is an important factor in HCC development among patients with advanced chronic hepatitis C...
  13. ncbi Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease
    Kengathevy Morgan
    Medical Services, VA Long Beach Healthcare System, Long Beach, California 90822, USA
    Eur J Gastroenterol Hepatol 20:843-54. 2008
    ..To determine whether expression of transcription factors and lipogenic enzymes is altered in liver and adipose tissue of mice with obesity, insulin resistance, and nonalcoholic fatty liver disease...
  14. ncbi Alcohol and hepatitis C
    M Mazen Jamal
    Long Beach VA Medical Center and University of California, Irvine, Long Beach, CA 90822, USA
    Dig Dis 23:285-96. 2005
    ..Alcohol use and hepatitis C are prominent risk factors for liver injury and this review offers the current understanding of each factor's effects on liver disease...
  15. ncbi Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  16. ncbi Alcohol and hepatocellular carcinoma
    Timothy R Morgan
    Gastroenterology Section, VA Medical Center, Long Beach, California, USA
    Gastroenterology 127:S87-96. 2004
    ..Alcohol use is increasing in many countries, suggesting that alcohol will continue to be a common cause of HCC throughout the world...
  17. ncbi Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease
    Elango Kathirvel
    Research Services, VA Long Beach Healthcare System, Long Beach, California 90822, USA
    Eur J Gastroenterol Hepatol 21:973-83. 2009
    ..The aim of this study was to determine whether CYP2E1 overexpression in the liver interferes with insulin signaling pathways in a mouse model of nonalcoholic fatty liver disease...
  18. ncbi Epidemiology of alcoholic liver disease
    Sarathy Mandayam
    Division of Gastroenterology, VA Medical Center, Long Beach, California, 90822, USA
    Semin Liver Dis 24:217-32. 2004
    ..A better understanding of the epidemiology of alcoholic liver disease will allow for improved diagnosis and management of this common problem...
  19. ncbi Liver disease in alcohol and hepatitis C
    M Mazen Jamal
    Division of Gastroenterology and Hepatology, VA Medical Center, 5901 E Seventh Street 111, Long Beach, CA 90822, USA
    Best Pract Res Clin Gastroenterol 17:649-62. 2003
    ..Recent alcohol use decreases the response rate to interferon treatment. The detrimental effects of small amounts (3 or fewer drinks per day) of alcohol consumption in patients with hepatitis C are not known...
  20. ncbi Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival
    Timothy R Morgan
    VA Long Beach Healthcare Systems, Long Beach, CA 90822, USA
    Gastroenterology 128:882-90. 2005
    ..Colchicine improved survival and reversed cirrhosis in several small clinical trials. We compared the efficacy and safety of long-term colchicine, as compared with placebo, in patients with advanced alcoholic cirrhosis...
  21. ncbi Hepatitis C and alcohol: fundamental and translational research directions
    Timothy R Morgan
    Department of Medicine, Veterans Adminstration Medical Center, Long Beach, California, USA
    Alcohol Clin Exp Res 27:726-31. 2003
    ..This article summarizes the panel's deliberations and their recommendations for future research on alcohol and hepatitis C...
  22. ncbi Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage
    Kengathevy Morgan
    VA Medical Center, 5901 E Seventh Street, Long Beach, CA 90822, USA
    Hepatology 36:122-34. 2002
    ..In conclusion, we have produced a transgenic mouse that expresses human CYP2E1 in the liver. When fed a nutritionally complete alcohol diet, transgenic mice develop more liver damage than nontransgenic mice...